CSL Limited (CSLLY)
USD 87.11
(0.13%)
USD 87.11
(0.13%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | 4.78 Billion USD | -19.16% |
| 2023 | 3.9 Billion USD | 12.62% |
| 2022 | 4.75 Billion USD | -4.53% |
| 2021 | 3.62 Billion AUD | 15.46% |
| 2020 | 4.34 Billion AUD | 8.64% |
| 2019 | 4 Billion AUD | 7.7% |
| 2018 | 2.68 Billion AUD | 38.38% |
| 2017 | 1.94 Billion AUD | 5.05% |
| 2016 | 1.84 Billion AUD | -5.48% |
| 2015 | 1.95 Billion AUD | 5.54% |
| 2014 | 1.85 Billion AUD | 7.89% |
| 2013 | 1.71 Billion AUD | 17.52% |
| 2012 | 1.46 Billion AUD | -0.86% |
| 2011 | 1.47 Billion AUD | 11.55% |
| 2010 | 1.32 Billion AUD | 2.46% |
| 2009 | 1.28 Billion AUD | 17.82% |
| 2008 | 1.09 Billion AUD | 40.49% |
| 2007 | 778.79 Million AUD | 220.34% |
| 2006 | 243.11 Million AUD | -62.65% |
| 2005 | 650.84 Million AUD | 127.96% |
| 2004 | 285.5 Million AUD | 65.68% |
| 2003 | 172.32 Million AUD | 1.0% |
| 2002 | 170.61 Million AUD | 147.24% |
| 2001 | 109.62 Million AUD | 1.14% |
| 2000 | 68.22 Million AUD | 43.95% |
| 1999 | 47.39 Million AUD | 16.42% |
| 1998 | 40.71 Million AUD | 2.64% |
| 1997 | 39.66 Million AUD | -32.03% |
| 1996 | 58.35 Million AUD | 30.74% |
| 1995 | 44.63 Million AUD | 83.3% |
| 1994 | 24.35 Million AUD | 15.92% |
| 1993 | 21 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | 1.62 Billion USD | 0.0% |
| 2024 FY | - USD | 21.3% |
| 2024 Q1 | 2.36 Billion USD | 71.26% |
| 2024 Q2 | 3 Billion USD | 0.0% |
| 2023 Q1 | 1.96 Billion USD | 104.52% |
| 2023 FY | - USD | 12.62% |
| 2023 Q4 | 1.27 Billion USD | 33.51% |
| 2023 Q3 | 954.39 Million USD | -61.58% |
| 2023 Q2 | 2.48 Billion USD | 26.36% |
| 2022 Q4 | 961.33 Million USD | 78.71% |
| 2022 Q2 | 2.44 Billion USD | 42.75% |
| 2022 FY | - USD | -4.53% |
| 2022 Q3 | 537.92 Million USD | -78.03% |
| 2022 Q1 | 1.71 Billion USD | 76.04% |
| 2021 Q4 | 974.31 Million USD | 71.14% |
| 2021 Q3 | 569.32 Million USD | -77.87% |
| 2021 Q1 | 1.8 Billion USD | 37.84% |
| 2021 Q2 | 2.57 Billion USD | 42.34% |
| 2021 FY | - AUD | 15.46% |
| 2020 Q4 | 1.31 Billion USD | 39.11% |
| 2020 FY | - AUD | 8.64% |
| 2020 Q2 | 1.8 Billion USD | 32.45% |
| 2020 Q1 | 1.36 Billion USD | 17.46% |
| 2020 Q3 | 942.73 Million USD | -47.68% |
| 2019 Q3 | 771.45 Million USD | -36.77% |
| 2019 FY | - AUD | 7.7% |
| 2019 Q1 | 1.18 Billion USD | 73.17% |
| 2019 Q4 | 1.15 Billion AUD | 50.13% |
| 2019 Q2 | 1.22 Billion USD | 2.61% |
| 2018 Q2 | 1.03 Billion USD | 0.5% |
| 2018 Q3 | 661.58 Million USD | -36.16% |
| 2018 Q4 | 686.69 Million AUD | 3.8% |
| 2018 FY | - AUD | 38.38% |
| 2018 Q1 | 1.03 Billion USD | 100.55% |
| 2017 Q2 | 849.28 Million USD | 6.07% |
| 2017 Q1 | 800.65 Million USD | 50.74% |
| 2017 FY | - AUD | 5.05% |
| 2017 Q4 | 514.12 Million AUD | -0.6% |
| 2017 Q3 | 517.21 Million USD | -39.1% |
| 2016 Q3 | 514.86 Million USD | -11.55% |
| 2016 Q4 | 531.16 Million AUD | 3.17% |
| 2016 FY | - AUD | -5.48% |
| 2016 Q2 | 582.07 Million USD | -3.47% |
| 2016 Q1 | 602.97 Million USD | -2.88% |
| 2015 Q3 | 626.46 Million USD | 5.82% |
| 2015 Q2 | 592.02 Million USD | 6.9% |
| 2015 Q1 | 553.79 Million USD | 15.19% |
| 2015 FY | - AUD | 5.54% |
| 2015 Q4 | 620.82 Million AUD | -0.9% |
| 2014 Q3 | 489.01 Million USD | -4.11% |
| 2014 FY | - AUD | 7.89% |
| 2014 Q1 | 487.95 Million USD | 13.65% |
| 2014 Q4 | 480.76 Million AUD | -1.69% |
| 2014 Q2 | 509.98 Million USD | 4.51% |
| 2013 FY | - AUD | 17.52% |
| 2013 Q2 | 424.12 Million USD | -0.06% |
| 2013 Q4 | 429.34 Million AUD | 13.7% |
| 2013 Q1 | 424.38 Million USD | 0.0% |
| 2013 Q3 | 377.62 Million USD | -10.96% |
| 2012 FY | - AUD | -0.86% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 11.55% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 2.46% |
| 2010 Q4 | - AUD | 0.0% |
| 2009 FY | - AUD | 17.82% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 40.49% |
| 2007 FY | - AUD | 220.34% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | - AUD | -62.65% |
| 2005 FY | - AUD | 127.96% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 FY | - AUD | 65.68% |
| 2004 Q4 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 1.0% |
| 2002 Q4 | - AUD | 0.0% |
| 2002 FY | - AUD | 147.24% |
| 2001 FY | - AUD | 1.14% |
| 2001 Q4 | - AUD | 0.0% |
| 2000 FY | - AUD | 43.95% |
| 2000 Q4 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 16.42% |
| 1998 FY | - AUD | 2.64% |
| 1998 Q4 | - AUD | 0.0% |
| 1997 FY | - AUD | -32.03% |
| 1997 Q4 | - AUD | 0.0% |
| 1996 FY | - AUD | 30.74% |
| 1995 FY | - AUD | 83.3% |
| 1994 FY | - AUD | 15.92% |
| 1993 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 6841.652% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 80873.714% |
| SQZ Biotechnologies Company | -64.14 Million USD | 7566.363% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 27670.524% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | -4992.615% |
| Mesoblast Limited | -62.38 Million USD | 7775.941% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 311873.908% |
| Genus plc | 73.7 Million USD | -6397.965% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 72534.208% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 135115.582% |
| Marizyme, Inc. | -34.28 Million USD | 14069.646% |
| ContraFect Corporation | -64.99 Million USD | 7467.806% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 54694.163% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 105906.312% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 341730.238% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 181196.395% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 206183.087% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | 924535.282% |
| Accustem Sciences Inc. | -3.74 Million USD | 127928.735% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 10030.122% |
| EV Biologics, Inc. | -1.26 Million USD | 378040.104% |
| Q BioMed Inc. | -617.62 Thousand USD | 775485.831% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | -133970.549% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 757366.693% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 209731.125% |
| Biomind Labs Inc. | -1.03 Million USD | 463007.025% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 9.87 Million USD | -48386.383% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 66973.567% |
| Skye Bioscience, Inc. | -13.54 Million USD | 35449.565% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 322068.627% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 19156100.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 123390.563% |
| IMV Inc. | -35.52 Million USD | 13581.257% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 30276.934% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 191509.782% |
| GB Sciences, Inc. | -1.41 Million USD | 337380.836% |
| Alpha Cognition Inc. | -9.7 Million USD | 49442.642% |
| HST Global, Inc. | -5303.00 USD | 90307473.185% |
| Halberd Corporation | -74.27 Thousand USD | 6447413.507% |
| Enzolytics Inc. | -2.12 Million USD | 225780.233% |
| Resverlogix Corp. | -11.74 Million USD | 40885.215% |
| Affymax, Inc. | -14.29 Million USD | 33601.227% |
| SYBLEU INC | -141.57 Thousand USD | 3382854.943% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 156449.167% |
| argenx SE | -216.02 Million USD | 2316.893% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 8753.933% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | -393408.628% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 319599.688% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | -1264008.71% |
| AVAX Technologies, Inc. | -6.11 Million USD | 78445.815% |
| Zenith Capital Corp. | -8.6 Million USD | 55747.223% |
| Genscript Biotech Corporation | -248.71 Million USD | 2025.462% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 27489911.147% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 195852.15% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | 2720746.165% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 12182.189% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 165676.08% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | 457802.865% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | -71222386.615% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 273757.299% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 249408.792% |
| BioStem Technologies, Inc. | -7.55 Million USD | 63499.855% |
| ONE Bio Corp. | 13.61 Million USD | -35079.494% |
| Reve Technologies, Inc. | -181.08 Thousand USD | 2644670.596% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 232914.779% |
| Agentix Corp. | -1.37 Million USD | 349214.566% |
| LadRx Corporation | 412.28 Thousand USD | -1161480.759% |
| Cell Source, Inc. | -4.27 Million USD | 112188.259% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | 1304219.318% |
| Regen BioPharma, Inc. | 1.46 Million USD | -326581.019% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | 511227.073% |
| NovAccess Global Inc. | -1.03 Million USD | 462896.085% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | -53989.763% |
| Itoco Inc. | -1.86 Million USD | 256333.965% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | 1261624.683% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 429221.864% |
| Kadimastem Ltd | -2.62 Million USD | 182581.126% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | 2002608.886% |
| CytoDyn Inc. | -18.02 Million USD | 26662.76% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | 6059900.833% |
| Mobile Lads Corp. | -2.24 Million USD | 213784.08% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | 39161110.712% |
| Qrons Inc. | -40.08 Thousand USD | 11948404.683% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | 986144.252% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | -907882.625% |
| Rebus Holdings, Inc. | -951 Thousand USD | 503675.184% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | 451037.373% |
| International Stem Cell Corporation | 202 Thousand USD | -2370692.079% |
| Bioxytran, Inc. | -3.82 Million USD | 125461.668% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 9097744.377% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 194622.026% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 13451.362% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -45 Thousand USD | 10642322.222% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 175008.692% |
| Neutra Corp. | -181.24 Thousand USD | 2642350.63% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 23856.139% |
| PureTech Health plc | -11.62 Million USD | 41288.613% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 23857.767% |
| IXICO plc | -707 Thousand USD | 677469.165% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 62416.2% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 10005.68% |
| CSL Limited | 4.73 Billion USD | -1.183% |
| Cellectis S.A. | -92.63 Million USD | 5269.696% |